Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-06-30

Study Completion Date

2017-03-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to evaluate the safety and tolerability of multiple sub-cutaneous injections of GeniusVac-Mel4, a dendritic cell-based cancer vaccine, in patients with melanoma. The secondary objectives are to determine immune response and clinical efficacy of such injections in patients with melanoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vaccination of Patients With Stage IV Melanoma With Dendritic Cells

NCT00125749

Melanoma Neoplasm Metastasis

COMPLETED PHASE1/PHASE2

Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study

NCT01973322

Malignant Melanoma of Skin Stage III Malignant Melanoma of Skin Stage IV

COMPLETED PHASE2

Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor

NCT01171469

Brain Tumor Glioblastoma Medulloblastoma +2 more

COMPLETED PHASE1

Dendritic Cell Based Therapy of Malignant Melanoma

NCT00197912

Advanced Melanoma

COMPLETED PHASE1/PHASE2

Dendritic Cell Vaccination in Patients With Advanced Melanoma

NCT03092453

Melanoma

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

GeniusVac-Mel4 is a drug product composed of an irradiated allogeneic plasmacytoid dendritic cell (PDC) line loaded with 4 melanoma peptides derived from Melan-A, gp100, Tyrosinase or Mage-A3. This cell line is HLA-A\*02:01, a phenotype found in 40% of the European population. This approach exploits the PDC line high capacity of boosting anti-tumor cytotoxic response against melanoma antigens in HLA-A\*02:01 melanoma patients. In the preclinical studies, a strong proof of concept was brought. Indeed, the GeniusVac-Mel4 capacity to induce high number of cytotoxic antitumor T-cells was shown in melanoma model, both in vivo in humanized mice and ex vivo with patients' PBMC (peripheral blood mononuclear cells) (Aspord et al 2010 and 2012).

It is planned to include patients in three dose-escalating groups (4, 20, 60 millions of GeniusVac-Mel4 cells). At least, 3 patients will be recruited in each dose group of the trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Melanoma Tumor Vaccines Effects of Immunotherapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GeniusVac-Mel4

Sub-cutaneous injections of GeniusVac-Mel4 in patients with melanoma.

Group Type EXPERIMENTAL

GeniusVac-Mel4

Intervention Type BIOLOGICAL

Multiple sub-cutaneous injections (1 injection weekly during 3 weeks) of GeniusVac-Mel4 (3 increasing dose groups) in patients with melanoma

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GeniusVac-Mel4

Multiple sub-cutaneous injections (1 injection weekly during 3 weeks) of GeniusVac-Mel4 (3 increasing dose groups) in patients with melanoma

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with histologically confirmed metastatic melanoma (at stage IIIC or stage IV under the AJCC 2009 classification not surgically resectable.
* Patients who do not respond to at least one line of systemic treatment
* Male and female (with β-HCG negative test)
* Patients HLA-A\*0201
* Age \> 18 years
* Blood parameters (Hemoglobin ≥ 10g/dl, Leucocytes ≥ 4000/μl,Lymphocytes ≥ 1000/μl, Platelets ≥100.000/μl, creatinin ≤ 2.0mg/dl, bilirubin ≤ 2.0mg/dl, ASAT and ALAT ≤ 2.5 fold the upper normal level)
* OMS performance score \< 3
* Informed written consent.

Exclusion Criteria

* Positive serology for HCV, HTLV, HIV, active hepatitis
* Protected persons according to French regulations articles L1121-5 to L1121-8 (Public Health Code)
* Non-pregnant women without effective contraception
* Any serious acute or chronic illness, for example: active infection, coagulation disorder.
* Presence of a second cancer in the 5 years preceding inclusion into the study with the exception of in situ cervical carcinoma or a cutaneous carcinoma or other melanoma.
* Intercurrent disease requiring corticosteroids.
* Any active autoimmune disease including insulin dependent diabetes mellitus. Vitiligo or autoimmune thyroid disease are not criteria for exclusion.
* Autoimmune eye disease.
* Evidence of immunosuppression for any reason
* Primary ocular melanoma
* Chemotherapy, immunotherapy or radiotherapy in the 4 weeks preceding inclusion (6 weeks in the case of nitroso-urea and mitomycin C).
* Treatment with drugs under development within 4 weeks.
* Cerebral metastases metastasis with the exception of: known metastasis previously treated by surgery or stereotactic radio-surgery, AND Cerebral metastasis, if still present, must be stable for at least 90 days before inclusion and documented with two consecutive MRI or scanner with contrast media, AND, asymptomatic
* Existence of any surgical or medical condition which, in the judgment of the Investigator, might interfere with this study.
* Patients who are not willing to comply with the provisions of this protocol.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No